Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals - Discussion

被引：0
|
作者：
Davidson, MH [1 ]
Wood, DA
Paoletti, R
Hobbs, R
Shepherd, J
Brown, WV
Hunninghake, DB
McKenney, JM
机构：
[1] Chicago Ctr Clin Res, Chicago, IL USA
[2] Charing Cross Hosp, Natl Heart & Lung Inst, London, England
[3] Univ Milan, Milan, Italy
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Emory Univ, Sch Med, Atlanta, GA USA
[7] Univ Minnesota, Minneapolis, MN USA
[8] Natl Clin Res, Richmond, VA USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2003年 / 91卷 / 5A期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：17C / 19C
页数：3
相关论文
共 50 条
  • [31] Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
    Pitt, B
    Waters, D
    Brown, WV
    van Boven, AJ
    Schwartz, L
    Title, LM
    Eisenberg, D
    Shurzinske, L
    McCormick, LS
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (02): : 70 - 76
  • [32] Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease
    Joel Hay
    Winnie M. Yu
    Talat Ashraf
    PharmacoEconomics, 1999, 15 : 47 - 74
  • [33] REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY
    GOLDSTEIN, MR
    NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16): : 1133 - 1133
  • [34] Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
    Bloom, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24): : 1854 - 1854
  • [35] Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
    Hay, JW
    Yu, WM
    Ashraf, T
    PHARMACOECONOMICS, 1999, 15 (01) : 47 - 74
  • [36] Do lipid lowering drugs reduce the risk of coronary heart disease?
    Pritzker, LB
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1998, 35 (06) : 603 - 621
  • [37] Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease
    Shepherd, James
    Kastelein, John J. P.
    Bittner, Vera A.
    Carmena, Rafael
    Deedwania, Prakash C.
    Breazna, Andrei
    Dobson, Stephen
    Wilson, Daniel J.
    Zuckerman, Andrea L.
    Wenger, Nanette K.
    MAYO CLINIC PROCEEDINGS, 2008, 83 (08) : 870 - 879
  • [38] The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease
    Szramka, M.
    Harriss, L.
    Ninnio, D.
    Windebank, E.
    Brack, J.
    Skiba, M.
    Krum, H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 117 (02) : 287 - 291
  • [39] Lipid-lowering treatment in coronary artery disease - How low should cholesterol go?
    Jones, PH
    DRUGS, 2000, 59 (05) : 1127 - 1135
  • [40] Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease
    Harnick, DJ
    Cohen, JL
    Schechter, CB
    Fuster, V
    Smith, DA
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (12): : 1416 - 1420
12345